for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Neurometrix Inc

NURO.OQ

Latest Trade

1.71USD

Change

0.01(+0.59%)

Volume

574

Today's Range

1.71

 - 

1.71

52 Week Range

0.82

 - 

6.20

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.70
Open
1.71
Volume
574
3M AVG Volume
6.17
Today's High
1.71
Today's Low
1.71
52 Week High
6.20
52 Week Low
0.82
Shares Out (MIL)
3.78
Market Cap (MIL)
6.36
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 NeuroMetrix Inc Earnings Call

Latest Developments

More

Neurometrix Says Q2 Revenue Fell 42% To $1.4 Million

NeuroMetrix Reports Q1 2020 Financial Results

Neurometrix Q4 Total Revenues Were $1.7 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Neurometrix Inc

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.

Industry

Medical Equipment & Supplies

Contact Info

1000 Winter St

WALTHAM, MA

02451-1436

United States

+1.781.8909989

http://www.neurometrix.com

Executive Leadership

Shai N. Gozani

Chairman of the Board, President, Chief Executive Officer, Secretary, Director

Thomas T. Higgins

Chief Financial Officer, Senior Vice President, Treasurer

Francis X. McGillin

Senior Vice President, Chief Commercial Officer

David E. Goodman

Independent Director

Nancy E. Katz

Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
0.87
Price To Book (MRQ)
1.16
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-65.30
Return on Equity (TTM)
-40.89

Latest News

Latest News

BRIEF-Neurometrix Reports DPNcheck Expansion In China

* NEUROMETRIX INC - REPORTS DPNCHECK EXPANSION IN CHINA Source text for Eikon: Further company coverage:

BRIEF-Neurometrix Signs Dpncheck® Collaboration Agreement With Biomedix

* NEUROMETRIX SIGNS DPNCHECK® COLLABORATION AGREEMENT WITH BIOMEDIX

BRIEF-Neurometrix Inc Says On June 1, Filed A Prospectus Supplement With SEC To Register Offer And Sale Of $315,000 Of Co's Common Stock

* NEUROMETRIX INC - ON JUNE 1, FILED A PROSPECTUS SUPPLEMENT WITH SEC TO REGISTER OFFER AND SALE OF $315,000 OF CO'S COMMON STOCK Source text: (https://bit.ly/2TZJPp7) Further company coverage:

BRIEF-NeuroMetrix Says Initiated Immediate Repayment Of Full Amount Of PPP Loan To Bank

* NEUROMETRIX INC - ON MAY 6, COMPANY INITIATED IMMEDIATE REPAYMENT OF FULL AMOUNT OF PPP LOAN TO BANK Source: (https://bit.ly/2La5K8q) Further company coverage:

BRIEF-Neurometrix - Filed A Prospectus Supplement To Register Offer And Sale Of $1.1 Mln Of Stock

* NEUROMETRIX INC - FILED A PROSPECTUS SUPPLEMENT TO REGISTER OFFER AND SALE OF $1.1 MILLION OF COMMON STOCK Source text: (https://bit.ly/2KCN80l) Further company coverage:

BRIEF-NeuroMetrix Reports Q1 2020 Financial Results

* QTRLY NET LOSS WAS $0.7 MILLION COMPARED TO NET INCOME OF $2.1 MILLION IN Q1 2019 Source text for Eikon: Further company coverage:

BRIEF-Neurometrix Says Quell Technology Selected For Use In Clinical Trial Of TENS For Fibromyalgia

* NEUROMETRIX INC - QUELL TECHNOLOGY SELECTED FOR USE IN LARGE, NIH-FUNDED CLINICAL TRIAL OF TENS FOR FIBROMYALGIA Source text for Eikon: Further company coverage:

BRIEF-NeuroMetrix Provides Quell Technology Commercial Strategy And Pipeline Update

* NEUROMETRIX PROVIDES QUELL® TECHNOLOGY COMMERCIAL STRATEGY AND PIPELINE UPDATE

BRIEF-Neurometrix Says Reached Settlement With Federal Trade Commission Of Previously Reported Investigation

* NEUROMETRIX - REACHED SETTLEMENT WITH FEDERAL TRADE COMMISSION OF PREVIOUSLY REPORTED INVESTIGATION INITIATED IN 2017 - SEC FILING

Pain device maker NeuroMetrix settles FTC false advertising case

Pain treatment device manufacturer NeuroMetrix and its founder will pay $4 million and turn over money earned through a collaboration with GlaxoSmithKline to resolve allegations it made false claims about its flagship product.

BRIEF-Neurometrix Inc Says May Offer And Sell Shares Of Common Stock Having Aggregate Offering Price Of Up To $2.2 Million From Time To Time

* NEUROMETRIX INC - MAY OFFER AND SELL SHARES OF COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $2.2 MILLION FROM TIME TO TIME Source text: (https://bit.ly/2SH7zhL) Further company coverage:

BRIEF-NeuroMetrix Q1 Revenue Rose 15 Percent To $4.9 Million

* QTRLY NET INCOME WAS $1.2 MILLION IN COMPARISON WITH A NET LOSS OF $3.2 MILLION IN Q1 2017 Source text for Eikon: Further company coverage:

BRIEF-Schrole Group Says Entered Alliance With International School Services, Inc​

* ENTERS STRATEGIC ALLIANCE WITH INTERNATIONAL SCHOOL SERVICES, INC Source text for Eikon: Further company coverage:

BRIEF-Neurometrix, Glaxosmithkline Announce Collaboration To Develop Quell Wearable Pain Relief Technology

* NEUROMETRIX AND GLAXOSMITHKLINE CONSUMER HEALTHCARE ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND EXPAND ACCESS TO QUELL WEARABLE PAIN RELIEF TECHNOLOGY

BRIEF-Neurometrix Reports Preliminary 2017 Financial Highlights

* NEUROMETRIX INC - PRELIMINARY GAAP REVENUE FOR Q4 OF 2017 IS ESTIMATED AT APPROXIMATELY $4.9 MILLION IN COMPARISON WITH $3.7 MILLION IN Q4 2016 Source text for Eikon: Further company coverage:

BRIEF-NeuroMetrix CFO reports purchase of 2,500 shares of co's common stock on Oct 23 at $1.77 per share

* NeuroMetrix Inc CFO Thomas Higgins reports purchase of 2,500 shares of co's common stock on Oct 23 at $1.77 per share - sec filing Source text (http://bit.ly/2gBQZj2) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up